Yang Zhilin, founder of fast-rising start-up Moonshot AI, has become the latest artificial intelligence entrepreneur to meet Chinese Premier Li Qiang, as Beijing steps up its push to accelerate the digital transformation of manufacturing. The 32-year-old was among a select group of business leaders and experts invited to a high-level symposium on Friday, where participants offered views on China’s...
Yang Zhilin, founder of fast-rising start-up Moonshot AI, has become the latest artificial intelligence entrepreneur to meet Chinese Premier Li Qiang, as Beijing steps up its push to accelerate the digital transformation of manufacturing. The 32-year-old was among a select group of business leaders and experts invited to a high-level symposium on Friday, where participants offered views on China’s economic resilience and future growth drivers. Li acknowledged that the external environment had...
Alphabet's Google Has Given Birth to 3 Millionaire-Maker Stocks Hiding in Plain Sight. All of Them Are Trading at Incredible Valuations Right Now. The Motley Fool
Alphabet's Google Has Given Birth to 3 Millionaire-Maker Stocks Hiding in Plain Sight. All of Them Are Trading at Incredible Valuations Right Now. The Motley Fool
Chips have fueled the AI gold rush, sending valuations of stocks like Nvidia (NASDAQ:NVDA) soaring as investors piled in. Six months later, though, the hardware leader sits flat while diversified players quietly compound gains. The next trillion-dollar shift isn’t going to be about raw compute power; rather, it will be the embedding of intelligence into ... Forget Nvidia: This Stock Will Be More V...
Chips have fueled the AI gold rush, sending valuations of stocks like Nvidia (NASDAQ:NVDA) soaring as investors piled in. Six months later, though, the hardware leader sits flat while diversified players quietly compound gains. The next trillion-dollar shift isn’t going to be about raw compute power; rather, it will be the embedding of intelligence into ... Forget Nvidia: This Stock Will Be More Valuable in Less Than 1 Year
Replimune ( REPL ) shares tumbled before a trading halt on Friday after the U.S. Food and Drug Administration (FDA) declined to approve its lead candidate RP1 (vusolimogene oderparepvec) for the second time. The Massachusetts-based biotech’s resubmitted Biologics License Application (BLA) for RP1 was undergoing regulatory review with a target of April 10, 2026, after the FDA initially rejected the...
Replimune ( REPL ) shares tumbled before a trading halt on Friday after the U.S. Food and Drug Administration (FDA) declined to approve its lead candidate RP1 (vusolimogene oderparepvec) for the second time. The Massachusetts-based biotech’s resubmitted Biologics License Application (BLA) for RP1 was undergoing regulatory review with a target of April 10, 2026, after the FDA initially rejected the drug for a skin cancer known as melanoma last year. The company had sought the approval of RP1 in combination with nivolumab, marketed by Bristol Myers ( BMY ) as Opdivo, for those with advanced melanoma who had undergone anti-PD-1 containing treatments previously. Issuing a complete response letter on Friday, the FDA said that it is unable to approve the BLA due to a lack of sufficient data demonstrating RP1's efficacy as a combination therapy for unresectable advanced cutaneous melanoma. More on Replimune Group Replimune: Multiple Shots On Goal But A High Risk Binary Approaches Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Biotech firm stocks rise on FDA vaccine head’s exit Replimune Group GAAP EPS of -$0.77 beats by $0.01
The post Rising Oil Prices Are Shaking Markets—One AI Prompt Lets You Explore Custom Portfolio Hedges in Minutes by Josh appeared first on Benzinga . Visit Benzinga to get more great content like this. Building a hedged portfolio often takes days, if not weeks of research and execution; an uncertain economy, such as times of rising oil prices or major geopolitical rifts, can make it even more chal...
The post Rising Oil Prices Are Shaking Markets—One AI Prompt Lets You Explore Custom Portfolio Hedges in Minutes by Josh appeared first on Benzinga . Visit Benzinga to get more great content like this. Building a hedged portfolio often takes days, if not weeks of research and execution; an uncertain economy, such as times of rising oil prices or major geopolitical rifts, can make it even more challenging to reduce your overall investment risks. With Public ’s latest innovation, Generated Assets, all you need is to type in a prompt into their AI to find new ways to hedge your portfolio. Think of it like an ETF with infinite possibilities — completely customizable and based on your thesis, not someone else’s. Here’s how it works: you type in an idea like “companies positioned to benefit from rising oil prices” or “defense tech companies growing revenue 25% year-over-year.” Public’s AI then dispatches a swarm of agents to scan every single US stock, evaluate them, and build a custom index around your thesis. What really stands out is how clearly it explains why each stock is included. And before you invest, you can backtest your idea against the S&P 500, so you’re making decisions with real context—not just guessing. Beyond Generated Assets, Public lets you invest in stocks, bonds, options, crypto, all in one place. They’ll even give you an uncapped 1% match when you transfer your investments over from another platform. Sign up today AI that informs Public also uses artificial intelligence to help investors understand why stock price movements happen. Investors get access to detailed AI-generated summaries directly on an asset’s performance chart, along with AI-generated earnings recaps. Alpha, Public’s AI-powered research assistant, allows any investor to ask questions about any asset’s real-time and historical market data, providing individuals with deeper analysis to inform their investment decision. Top-notch security Public uses state-of-the-art encryption to keep...
photoschmidt Citi Research downgraded six application software stocks to Neutral from Buy as it contends AI concerns are likely to intensify in the months ahead. The companies downgraded include Similarweb ( SMWB ), Docusign ( DOCU ), Autodesk ( ADSK ), Nice ( NICE ), CCC Intelligent Solutions Holdings ( CCC ), and Veeva Systems ( VEEV ). Shares of all six companies were down during Friday trading...
photoschmidt Citi Research downgraded six application software stocks to Neutral from Buy as it contends AI concerns are likely to intensify in the months ahead. The companies downgraded include Similarweb ( SMWB ), Docusign ( DOCU ), Autodesk ( ADSK ), Nice ( NICE ), CCC Intelligent Solutions Holdings ( CCC ), and Veeva Systems ( VEEV ). Shares of all six companies were down during Friday trading. "We believe most of these are good companies and may be well positioned long-term but don’t have exciting 12-month catalysts," said Citi analysts, led by Tyler Radke, in a Friday investor report. "This more selective approach would allow us to be more agile with our ratings should we see signs of AI acceleration play out." Citi also lowered its price targets on these stocks. Similarweb was reduced to $3 from $8.50, Docusign to $50 from $99, Autodesk to $246 from $331, Nice to $119 from $184, CCC to $6 from $10, and Veeva to $176 from $291. "Put simply, we see risk that concerns around software application architecture, business model durability, and terminal value intensify in the months ahead," Radke noted. "Privately held AI companies are on track to add $100B+ of net-new revenue in the years ahead, materially eclipsing the $50B of traditional application software NNACV. While AI budgets may be mostly additive vs. replacement to software, checks indicate an uptick in software optimization costs/vendor consolidation." More on DocuSign, NICE, Veeva Veeva Systems: Growth Has More Legs Now Docusign: Stabilizing Business At A Great Price Docusign: Buy The SaaS Panic Docusign in focus as BofA reinstates with Underperform rating Enterprise software joins Monday's rally, with Palantir and AppLovin leading
Tesla stock is poised to drop for the eight week in a row, as its rough 2026 start rolls on. This as first quarter earnings are coming later this month.
Tesla stock is poised to drop for the eight week in a row, as its rough 2026 start rolls on. This as first quarter earnings are coming later this month.
Tesla stock is poised to drop for the eight week in a row, as its rough 2026 start rolls on. This as first quarter earnings are coming later this month.
Tesla stock is poised to drop for the eight week in a row, as its rough 2026 start rolls on. This as first quarter earnings are coming later this month.
Hi, it’s Crystal Tse, looking at Italian fashion’s shifting attitude to M&A. Also today, finance titans bet that Mideast resilience will outweigh the fallout of war. Today’s top stories Dolce & Gabbana co-founder steps down, mulls stake options . Engie eyes disposals in US, France to fund UK acquisition. Student landlord Unite hires Goldman to ramp up asset sales. Warburg launches Europe defense f...
Hi, it’s Crystal Tse, looking at Italian fashion’s shifting attitude to M&A. Also today, finance titans bet that Mideast resilience will outweigh the fallout of war. Today’s top stories Dolce & Gabbana co-founder steps down, mulls stake options . Engie eyes disposals in US, France to fund UK acquisition. Student landlord Unite hires Goldman to ramp up asset sales. Warburg launches Europe defense fund with Munich Re backing. Dolce sans Gabbana This season’s hottest trend in Italian fashion? M&A. As my colleagues Luca Casiraghi, Antonio Vanuzzo, Giulia Morpurgo and Angelina Rascouet report , Dolce & Gabbana’s co-founder Stefano Gabbana is weighing options for his roughly 40% stake in the company after stepping down as its chairman. D&G described the resignation as part of the “natural evolution” of its structure and governance. For advisory bankers covering the consumer sector, it may also speak to some shifting attitudes to dealmaking. Unlike their French peers, which have been consolidating under the likes of LVMH and Gucci-owner Kering, Italy’s fashion houses have largely remained controlled by influential founders and their families—often with a powerful patriarch or matriarch running the show. But faced with a global slump in demand for luxury goods there are signs that they’re opening up to more ambitious moves. Prada last year bought Versace, which is now helmed by Prada heir Lorenzo Bertelli. Elsewhere, the relatives of the late Giorgio Armani are seeking to monetize the famous brand via a stake sale . And Ferragamo—a rumored takeover target following the death of the founder’s widow in 2018—has reportedly been exploring the possibility of outside capital. D&G, which Gabbana co-founded with his then-partner Domenico Dolce in the 1980s, has so far worked to preserve its status as one of the last major, independent houses by expanding into beauty, real estate and hospitality. It’s also sought collaborations like the one with Kim Kardashian’s Skims brand, in the ...
Dow ( DOW ) declares $0.35/share quarterly dividend , in line with previous. Forward yield 3.64% Payable June 12; for shareholders of record April 29; ex-div April 29. See DOW Dividend Scorecard, Yield Chart, & Dividend Growth. More on Dow Dow Inc.: Looking For A New Buying Opportunity After Taking Epic Fury Profits Dow Inc. (DOW) Presents at JPMorgan Industrials Conference 2026 - Slideshow Dow In...
Dow ( DOW ) declares $0.35/share quarterly dividend , in line with previous. Forward yield 3.64% Payable June 12; for shareholders of record April 29; ex-div April 29. See DOW Dividend Scorecard, Yield Chart, & Dividend Growth. More on Dow Dow Inc.: Looking For A New Buying Opportunity After Taking Epic Fury Profits Dow Inc. (DOW) Presents at JPMorgan Industrials Conference 2026 - Slideshow Dow Inc. (DOW) Presents at JPMorgan Industrials Conference 2026 Transcript Iran's attack on Saudi Arabia's giant Jubail petrochem complex adds to global supply risk Dow downgraded at BofA amid rally driven by temporary earnings surge
Red Cat moves from a startup to a defense-scale producer, boosting capacity across U.S. sites and hitting 1,000 drones monthly before contracts are finalized.
Red Cat moves from a startup to a defense-scale producer, boosting capacity across U.S. sites and hitting 1,000 drones monthly before contracts are finalized.
The post Billions of People Lack Timely Access to Diagnostics. A Space-Tested Technology Backed by NASA and the NIH Aims to Fix That, and is Nearing FDA Registration by Benzinga Contributors appeared first on Benzinga . Visit Benzinga to get more great content like this. NASA had a problem. It needed a way to ensure its astronauts were staying healthy while in space, where there are no doctors or ...
The post Billions of People Lack Timely Access to Diagnostics. A Space-Tested Technology Backed by NASA and the NIH Aims to Fix That, and is Nearing FDA Registration by Benzinga Contributors appeared first on Benzinga . Visit Benzinga to get more great content like this. NASA had a problem. It needed a way to ensure its astronauts were staying healthy while in space, where there are no doctors or labs available to do bloodwork. Down here on Earth, more than half the global population face the same issue. The World Health Organization estimates 4.5 billion people lack timely access to diagnostics testing, and it often takes weeks for physicians to interpret results. That means delays in care for the more than 194 million U.S. adults managing chronic conditions. The potential solution to both of these issues? rHEALTH’s at-home diagnostics tools that deliver lab-quality results in up to 20 minutes from a self-collected blood sample. This patent-protected technology has been tested on the International Space Station, and is now being adapted for point-of-care settings and eventually private homes. With the technology and potential to run more than 100 tests in a single device and backing from NASA and the National Institutes of Health, rHEALTH aims to disrupt the $323 billion blood diagnostics market. FDA registration is targeted within approximately 12 months. Backed by Science The rHEALTH ONE was tested aboard the International Space Station by astronaut Samantha Cristoforetti in some of the most extreme conditions. The technology’s results have been published in top, peer-reviewed science journals and was specifically picked by NASA following a review of competing diagnostic platforms for space use. The system was also founded by a Harvard/MIT-trained physician who invested $2 million of his personal money into the company. There are 17 U.S. patents covering its device architecture, diagnostic algorithms, and miniaturized components. Strategic partnerships have been ...